Influence of polyunsaturated fatty acids on vasoconstrictions induced by 8-iso-PGF(2α) and 8-iso-PGE2

Pharmacology

Volumn 60, Issue 3, 2000, Pages 155-160

  Sametz, Wolfgang ^a   Jeschek, Mirjam ^b   Juan, Heinz ^b   Wintersteiger, Reinhold ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b NONE

Author keywords

8 iso PGE2; 8 iso PGF(2 ); Dihomo linolenic acid; Docosahexaenoic acid; Eicosapentaenoic acid; U 46619; Vasoconstriction

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 8 ISOPROSTAGLANDIN E2; 8 ISOPROSTAGLANDIN F2 ALPHA; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INDOMETACIN; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN E1; PROSTAGLANDIN E2 DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT;

ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOSE RESPONSE; NONHUMAN; PEROXIDATION; PRIORITY JOURNAL; VASOCONSTRICTION;

EID: 0034027640     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028360     Document Type: Article

References (44)

1. Morrow JD, Harris TM, Roberts LJ II: Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal Biochem 1990;184:1-10.
2. 2-like compounds arc produced in vivo in humans by a noncyclooxygenase free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-9387.
3. 2α, is formed in vivo. Biochem Biophys Acta 1994;1210:244-248.
4. Nicosia S, Patrono C: Eicosanoid biosynthesis and action: Novel opportunities for pharmacological intervention. FASEB J 1989;3:1941-1948.
5. Morrow JD, Minton TA, Mulkundan CR, Campell MD, Zackert WE, Daniel VC, Badr KF, Blair IA, Roberts LJ II: Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem 1994;269:4317-4326.
6. 2α. Br J Pharmacol 1996;119:1276-1280.
7. 1 in a peripheral vascular system. Prostaglandins Leukot Essent Fatty Acids 1996;55(suppl 1):100.
8. Sametz W, Prasthofer S, Krobuschek T, Wintersteiger R, Juan H: Vascular effects of isoprostanes. Naunyn-Schmiedeberg's Arch Pharmacol 1997;356(suppl 1):R7.
9. Sametz W, Grobuschek T, Hammer-Kogler S, Juan H, Wintersteiger R: Influence, of isoprostanes on vasoconstrictor effects of noradrenaline and angiotensin II. Eur J Pharmacol 1999; 378:47-55.
10. Drevon CA, Baksaas I, Krokan HE: Omega-3 Fatty Acids: Metabolism and Biological Effects. Basel. Birkhäuser, 1993.
11. Zoller N, Tato F: Fatty acids composition of the diet: Impact on serum lipids and atherosclerosis. A review. Clin Invest 1992;70:968-1009.
12. Horrobin DF: Prostaglandin El: Physiological significance and clinical use. Wien Klin Wochenschr 1988;14:471-477.
13. 2. Br J Haematol 1984;58:567-578.
14. Juan H, Sametz W: Vasoconstriction induced by noradrenaline and angiotensin II is antagonized by cicosapentaenoic acid independent of formation of trienoic eicosanoids. Naunyn-Schmiedeberg's Arch Pharmacol 1986;332: 288-292.
15. Juan H, Sametz W, Saria A, Pöch G: Eicosapentaenoic acid inhibits vasoconstrictor-and noradrenaline-potentiating effects of neuropeptide Y in the isolated rabbit ear. J Auton Nerv Syst 1988;22:237-242.
16. Engler MB: Effect of omega-3 fatty acids, docosahexaenoic and eicosapentaenoic, on norepinephrine-induced contractions. Can J Physiol Pharmacol 1992;70:675-679.
17. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100:2028-2034.
18. 2 alpha generation during coronary rcpcrfusion: A potential quantitative marker of oxidant stress in vivo. Circulation 1997;95:2492-2499.
19. Mallat Z, Philip I, Lebret M, Chatcl D, Maclouf J, Tedgui A: Elevated levels of 8-iso-prostaglandin F-2 alpha in pericardial fluid of patients with heart failure: A potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998;16:1536-1539.
20. 2 alpha is increased in hypercholesterolemia. Arter Thromb Vasc Biol 1997;17:3230-3235.
21. Knapp HR, FitzGerald GA: The antihyperten-sive effects of fish oil: A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med 1989;320: 1037-1043.
22. Bonaa KH, Bjerve KS, Straume B, Gram IT, Thelle D: Effect of eicosapentaenoic and docosahexacnoic acids on blood pressure in hypertension: A population-based intervention trial from the Tromso study. N Engl J Med 1990; 322:795-801.
23. Kremer JM: Medicinal Fatty Acids in Inflammation. Basel, Birkhauser, 1998.
24. Boberg M, Vessby B, Selibus I: Effects of dietary supplementation with n-6 and n-3 long-chain PUFAs on serum lipoproteins and platelet function in hyperlipidemic patients. Acta Med Scand 1986;220:153-160.
25. Rand ML, Hennisscn AAHM, Hornstra G: Effects of dietary sunflowersecd oil and marine oil on platelet membrane fluidity, arterial thrombosis, and plalelet responses in rats. Atherosclerosis 1986;62:267-277.
26. Lagarde M, Burtin M, Decchavanne M, Sicard B, Coiffier B: Dihomogammalinolenic acid (20:3 omega 6) is more anti-aggregatory than cicosapentaenoic (20:5 omega 3) in a platelet-endothelial cell mixture. Prostaglandins Med 1980;4:177-183.
27. Mortensen JZ, Schmidt EB, Nielsen AH, Dyerberg J: The effect of n-6 and n-3 PUFAs on hemostasis, blood lipids and blood pressure. Thromb Haemostas 1983;50:543-546.
28. Norris PG, Hjones CJ, Weston MG: Effects of dietary supplementation with fish oil on systolic blood pressure in mild essential hypertension. Br Med J 1986;293:104-105.
29. Singer P, Jaeger W, Berger I, Barleben H, Wirth M, Richter-Heinrich E, Voigt S. Gödicke W: Effects of dietary oleic, linolcic and alpha-linolenic acids on blood pressure, serum lipids, lipoproteins and the formation of eicosanoid precursors in patients with mild essential hypertension. J Hum Hypertens 1990;4:227-233.
30. Yanagisawa A, Lefer AM: Vasoactive effects of eicosapentaenoic acid on isolated vascular smooth muscle. Basic Res Cardiol 1987;82: 186-196.
31. Yoshimura T, Ito M, Matsui K, Fujisaki S: Effects of highly purified eicosapentaenoic acid on vascular reactivity in angiotensin II and norepinephrine in the rabbit. Prostaglandins 1986; 32:179-188.
32. 2) in isolated guinea pig hearts. J Cardiovasc Pharmacol 1997;29:789-794.
33. 2α in the rat. J Clin Invest 1992;90: 1.36-141.
34. Morrow JD, Roberts LJ: The isoprostanes: Unique bioactive products of lipd peroxidation. Prog Lipid Res 1997;36:1-21.
35. 2-isoprostane receptors on rat vascular smooth muscle cells. Cell Physiol 1993;33:C1619-C1624.
36. Hirata Y, Unieniura K, Uematsu T, Nakashima M: An experimental myocardial infarction model in the rat and its properties. Jpn J Pharmacol 1995;67:51-57.
37. Squadrito F, Ioculano M, Altavilla D, Zingarelli B, Canali P, Campo GM, Saitta A, Oriti S, Spignoli G, Caputi AP: G619, a dual thromboxane synthasc inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leucocyte accumulation following coronary artery occlusion and reperfusion in rats. Pharmacology 1993; 47:167-175.
38. Guth BD, Muller TH: DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol 1997;92:181-190.
39. Goodnight SH: Fish oil and vascular disease. Trends Cardiovasc Med 1991;1:112-116.
40. 1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans. Cardiovasc Drugs Ther 1997;11:441-448.
41. 1 infusions in outpatients with severe congestive heart failure. J Heart Lung Transplant 1997;16:556-562.
42. 1 on cerebral blood flow in patients with chronic cerebral infarction. Intern Med 1998;37:841-846.
43. Merion RM: Prostaglandins in liver transplantation. Adv Exp Med Biol 1997;433:13-18.
44. Bauer J, Dapper F, Demirakca S, Knothe C, Thul J, Hagel KJ: Perioperative management of pulmonary hypertension after heart transplantation in childhood. J Heart Lung Transplant 1997;16:1238-1247.